The stock of Angiodynamic Inc (ANGO) has gone up by 22.69% for the week, with a 22.52% rise in the past month and a 18.54% rise in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are 3.48% for ANGO. The simple moving average for the last 20 days is 23.80% for ANGO stock, with a simple moving average of 32.69% for the last 200 days.
Is It Worth Investing in Angiodynamic Inc (NASDAQ: ANGO) Right Now?
The stock has a 36-month beta value of 0.67. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ANGO is 38.70M, and at present, short sellers hold a 2.93% of that float. On December 09, 2024, the average trading volume of ANGO was 490.45K shares.
ANGO) stock’s latest price update
Angiodynamic Inc (NASDAQ: ANGO) has seen a rise in its stock price by 25.14 in relation to its previous close of 7.00. However, the company has experienced a 22.69% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-12-09 that LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow.
Analysts’ Opinion of ANGO
Many brokerage firms have already submitted their reports for ANGO stocks, with Oppenheimer repeating the rating for ANGO by listing it as a “Outperform.” The predicted price for ANGO in the upcoming period, according to Oppenheimer is $12 based on the research report published on April 05, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ANGO reach a price target of $19. The rating they have provided for ANGO stocks is “Buy” according to the report published on September 25th, 2023.
Raymond James gave a rating of “Outperform” to ANGO, setting the target price at $13 in the report published on April 17th of the previous year.
ANGO Trading at 27.46% from the 50-Day Moving Average
After a stumble in the market that brought ANGO to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 6.18% of gains for the given period.
Volatility was left at 3.48%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +23.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.67% upper at present.
During the last 5 trading sessions, ANGO rose by +24.09%, which changed the moving average for the period of 200-days by +53.02% in comparison to the 20-day moving average, which settled at $7.08. In addition, Angiodynamic Inc saw 11.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANGO starting from Nighan Warren JR, who purchase 768 shares at the price of $6.09 back on Oct 07 ’24. After this action, Nighan Warren JR now owns 45,777 shares of Angiodynamic Inc, valued at $4,677 using the latest closing price.
Nighan Warren JR, the SVP Quality and Regulatory of Angiodynamic Inc, purchase 100 shares at $6.08 during a trade that took place back on Oct 10 ’24, which means that Nighan Warren JR is holding 45,877 shares at $608 based on the most recent closing price.
Stock Fundamentals for ANGO
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.5 for the gross margin
The net margin for Angiodynamic Inc stands at -0.83. The total capital return value is set at -0.2. Equity return is now at value -77.85, with -61.72 for asset returns.
Currently, EBITDA for the company is -14.29 million with net debt to EBITDA at 3.09. When we switch over and look at the enterprise to sales, we see a ratio of 1.04. The receivables turnover for the company is 7.4for trailing twelve months and the total asset turnover is 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
To sum up, Angiodynamic Inc (ANGO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
